Celator gains $20M round for cancer drug dev - FierceBiotech
Links shared publicly online about this topic.
- 905total visits
Celator gains $20M round for cancer drug dev - FierceBiotech
Princeton, NJ-based Celator Pharmaceuticals has closed a $20 million Series D to back its development work on new cancer therapies. Its lead drug--CPX-351 (Cytarabine:Daunorubicin) Liposome Read more...
View full resource at fiercebiotech.com
Tags: Cancer, Cancer Medication, Drug, Pharma
Most Recently Shared on September 1, 2010 at 4:21 pm By:
Celator gains $20M round for cancer drug dev. http://bit.ly/dsFkfw
Advertisement
